Trial Profile
A Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of IV Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy (PCV)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Mar 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Verteporfin
- Indications Polypoidal choroidal vasculopathy
- Focus Proof of concept; Therapeutic Use
- Acronyms ATLANTIC
- 08 Jan 2020 Status changed from active, no longer recruiting to completed.
- 09 Oct 2019 This trial has been completed in Portugal, according to European Clinical Trials Database. (2018-09-05)
- 18 May 2019 This trial has been completed in Spain, according to European Clinical Trials Database.